Professor | Xiaowu Dong | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Xiaowu Dong
Contact Information	dongxw@zju.edu.cn
Language ability	Chinese, English
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Xiaowu Dong

Contact Information

dongxw@zju.edu.cn

Language ability

Chinese, English

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	2004.9-2009.6 Ph.D. in Medicinal Chemistry: Zhejiang University 2000.9-2004.6 Bachelor's in Pharmaceutical Preparations: Zhejiang University Published over 100 papers in international journals H-index of 25 Received Zhejiang Province Outstanding Youth Fund Authorized 20 national invention patents, including 4 international patents
Work Experience	2020.1-present - Zhejiang University College of Pharmaceutical Sciences - Professor 2015.1-2019.12 - Zhejiang University College of Pharmaceutical Sciences - Associate Professor 2011.9-2013.1 - University of Hong Kong Department of Chemistry - Postdoctoral Researcher 2011.7-2014.12 - Zhejiang University College of Pharmaceutical Sciences - Lecturer 2009.7-2011.6 - Zhejiang University College of Pharmaceutical Sciences - Postdoctoral Researcher
Awards	2020: Zhejiang Province Science and Technology Progress Award - Second Prize 2018: Zhejiang University Shihua Yu Young Teacher Award - Second Prize 2017: Zhejiang University Excellent Teaching Award - Second Prize 2015: Zhejiang University Young Post Expert Honorary Title

University/Lab Affiliation and Title

Zhejiang University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

2004.9-2009.6 Ph.D. in Medicinal Chemistry: Zhejiang University
2000.9-2004.6 Bachelor's in Pharmaceutical Preparations: Zhejiang University
Published over 100 papers in international journals
H-index of 25
Received Zhejiang Province Outstanding Youth Fund
Authorized 20 national invention patents, including 4 international patents

Work Experience

2020.1-present - Zhejiang University College of Pharmaceutical Sciences - Professor
2015.1-2019.12 - Zhejiang University College of Pharmaceutical Sciences - Associate Professor
2011.9-2013.1 - University of Hong Kong Department of Chemistry - Postdoctoral Researcher
2011.7-2014.12 - Zhejiang University College of Pharmaceutical Sciences - Lecturer
2009.7-2011.6 - Zhejiang University College of Pharmaceutical Sciences - Postdoctoral Researcher

Awards

2020: Zhejiang Province Science and Technology Progress Award - Second Prize
2018: Zhejiang University Shihua Yu Young Teacher Award - Second Prize
2017: Zhejiang University Excellent Teaching Award - Second Prize
2015: Zhejiang University Young Post Expert Honorary Title

Areas of Focus	Targeted protein degradation and druggability optimization AI-based drug design and application in new drug discovery
Publications	Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors, Duan, H.; Zhang, J.; Gui, R.; Lu, Y.; Pang, A.; Chen, B.; Shen, L.; Yu, H.; Li, J.; Xu, T.; Wang, Y.; Yao, X.; Zhang, B.; Lin, N.; Dong, X.; Zhou, Y.; Che, J., 2024 Discovery of Orally Bioavailable Phenyltetrazolium Derivatives for the Acute Treatment and the Secondary Prevention of Ischemic Stroke, Lu, Y.; Lin, H.; Xu, Y.; Shen, Z.; Guo, Y.; Jin, Y.; Shi, Q.; Chen, H.; Zhuang, Y.; Huang, W.; Che, J.; Dai, H.; Dong, X., 2024 Discovery of a Potent CDKs/FLT3 PROTAC with Enhanced Differentiation and Proliferation Inhibition for AML, Wu, M.; Wang, W.; Mao, X.; Wu, Y.; Jin, Y.; Liu, T.; Lu, Y.; Dai, H.; Zeng, S.; Huang, W.; Wang, Y.; Yao, X.; Che, J.; Ying, M.; Dong, X., 2024 Discovery of Potent CSK Inhibitors through Integrated Virtual Screening and Molecular Dynamic Simulation, Chen, R.; Wang, Y.; Shen, Z.; Ye, C.; Guo, Y.; Lu, Y.; Ding, J.; Dong, X.; Xu, D.; Zheng, X., 2024 Discovery and Characterization of Novel FGFR1 Inhibitors in Triple-Negative Breast Cancer via Hybrid Virtual Screening and Molecular Dynamics Simulations, Wang, Y.; Shen, Z.; Chen, R.; Chi, X.; Li, W.; Xu, D.; Lu, Y.; Ding, J.; Dong, X.; Zheng, X., 2024 Discovery of Potent Small Molecule Ubiquitin-Specific Protease 10 Inhibitors with Anti-Hepatocellular Carcinoma Activity through Regulating YAP Expression, Lu, Y.; Gao, J.; Wang, P.; Chen, H.; He, X.; Luo, M.; Guo, Y.; Li, L.; Zhuang, W.; Zhang, B.; Lin, N.; Li, J.; Zhou, Y.; Dong, X.; Che, J., 2024 Blocking Ubiquitin-Specific Protease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl-CoA Desaturase, Guan, X.; Wang, Y.; Yu, W.; Wei, Y.; Lu, Y.; Dai, E.; Dong, X.; Zhao, B.; Hu, C.; Yuan, L.; Luan, X.; Miao, K.; Chen, B.; Cheng, X.-D.; Zhang, W.; Qin, J.-J., 2024 Discovery of Novel, Potent, Selective and Orally Bioavailable HPK1 Inhibitor for Enhancing the Efficacy of Anti-PD-L1 Antibody, Zeng, S.; Wu, M.; Jin, Y.; Ye, Y.; Xia, H.; Chen, X.; Che, J.; Wang, Z.; Wu, Y.; Dong, X.; Chen, Y.; Huang, W., 2024 Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors, Guo, Y.; Shen, Z.; Zhao, W.; Lu, J.; Song, Y.; Shen, L.; Lu, Y.; Wu, M.; Shi, Q.; Zhuang, W.; Qiu, Y.; Sheng, J.; Zhou, Z.; Fang, L.; Che, J.; Dong, X., 2024 Discovery of N-(1-(6-Oxo-1,6-Dihydropyrimidine)-Pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium Tuberculosis, Yang, L.; Hu, X.; Lu, Y.; Xu, R.; Xu, Y.; Ma, W.; Alam, M. S.; Zhang, T.; Chai, X.; Lei, Y.; Ye, Q.; Dong, X.; Kang, Y.; Che, J.; Hou, T.; Li, D., 2024 Combining AI and Traditional Screening for Discovery of a Potent ROCK2 Inhibitor against Lymphoma, Lu, Y.; Shen, Z.; Shen, L.; Ying, J.; Gao, J.; Zhao, J.; Geng, S.; Chi, X.; Zhang, T.; Xu, L.; Zhang, Q.; Dong, X.; Xu, D., 2024 A Microenvironment-Responsive Small-Molecule Probe and Application in Quick Acute Myocardial Infarction Imaging, Lu, J.; Wu, Y.; Zhan, S.; Zhong, Y.; Guo, Y.; Gao, J.; Zhang, B.; Dong, X.; Che, J.; Xu, Y., 2024 Discovery of a Potent and Selective PARP1 Degrader Promoting Cell Cycle Arrest via Intercepting CDC25C-CDK1 Axis for Treating Triple-Negative Breast Cancer, Wu, Y.; Wu, M.; Zheng, X.; Yu, H.; Mao, X.; Jin, Y.; Wang, Y.; Pang, A.; Zhang, J.; Zeng, S.; Xu, T.; Chen, Y.; Zhang, B.; Lin, N.; Dai, H.; Wang, Y.; Yao, X.; Dong, X.; Huang, W.; Che, J., 2024 ADCdb: The Database of Antibody–Drug Conjugates, Shen, L.; Sun, X.; Chen, Z.; Guo, Y.; Shen, Z.; Song, Y.; Xin, W.; Ding, H.; Ma, X.; Xu, W.; Zhou, W.; Che, J.; Tan, L.; Chen, L.; Chen, S.; Dong, X.; Fang, L.; Zhu, F., 2024 Structure-Based Identification of New Orally Bioavailable BRD9-PROTACs for Treating Acute Myelocytic Leukemia, Zhang, J.; Duan, H.; Gui, R.; Wu, M.; Shen, L.; Jin, Y.; Pang, A.; Yu, X.; Zeng, S.; Zhang, B.; Lin, N.; Huang, W.; Wang, Y.; Yao, X.; Li, J.; Dong, X.; Zhou, Y.; Che, J., 2023 Identification of Potential JNK3 Inhibitors: A Combined Approach Using Molecular Docking and Deep Learning-Based Virtual Screening, Yao, C.; Shen, Z.; Shen, L.; Kadier, K.; Zhao, J.; Guo, Y.; Xu, L.; Cao, J.; Dong, X.; Yang, B., 2023 Peripheral immune cell profiling of double-hit lymphoma by mass cytometry, Lei, T.; Wu, Y.; Zhang, W.; Lu, J.; Han, S.; Zhuang, Y.; Dong, X.; Yang, H., 2023 TransFoxMol: predicting molecular property with focused attention, Gao, J.; Shen, Z.; Xie, Y.; Lu, Y.; Chen, S.; Bian, Q.; Guo, Y.; Shen, L.; Wu, J.; Zhou, B.; Hou, T.; He, Q.; Che, J.; Dong, X., 2023 A practical \"pre TACs-cytoblot” platform accelerates the streamlined development of PROTAC-based protein degraders, Rao, Z.; Li, K.; Hong, J.; Chen, D.; Ding, B.; Jiang, L.; Qi, X.; Hu, J.; Yang, B.; He, Q.; Dong, X.; Cao, J.; Zhu, CL., 2023 ClusterX: a novel representation learning-based deep clustering framework for accurate visual inspection in virtual screening, Chen, S.; Gao, J.; Chen, J.; Xie, Y.; Shen, Z.; Xu, L.; Che, J.; Wu, J.; Dong, X., 2023 Akt inhibitor Hu7691 induces differentiation of neuroblastoma cells, Bing, S.; Xiang, S.; Xia, Z.; Wang, Y.; Guan, Z.; Che, J.; Xu, A.; Dong, X.; Cao, J.; Yang, B.; Wang, J.; He, Q.; Ying, M., 2023 Discovery of Novel Oxazepine Derivatives as Akt/ROCK Inhibitiors for Growth Arrest and Differentiation Induction in Neuroblastoma Treatment, Che, J.; Bing, S.; Lu, J.; Jin, Z.; Gao, J.; Sheng, H.; Li, D.; Yang, B.; He, Q.; Ying, M.; Dong, X., 2023 An updated patent review of AKT inhibitors(2020-present), Li, L.; Guo, Y.; Lu, Y.; Xu，Y.; Lu, Y.; Zhu, X.; Dong, X.; Che, J., 2023 Targeted delivery of cathepsin-activatable near-infrared flurescenece probe for ultrahigh specific imaging of peritoneal metastasis, Lu, J.; Guo, Y.; Hao, H.; Ma, J.; Lu, Y.; Sun, Y.; Shi, Z.; Dong, X.; Zhang, B.; Fang, L.; Che,

Areas of Focus

Targeted protein degradation and druggability optimization
AI-based drug design and application in new drug discovery

Publications

Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors, Duan, H.; Zhang, J.; Gui, R.; Lu, Y.; Pang, A.; Chen, B.; Shen, L.; Yu, H.; Li, J.; Xu, T.; Wang, Y.; Yao, X.; Zhang, B.; Lin, N.; Dong, X.; Zhou, Y.; Che, J., 2024
Discovery of Orally Bioavailable Phenyltetrazolium Derivatives for the Acute Treatment and the Secondary Prevention of Ischemic Stroke, Lu, Y.; Lin, H.; Xu, Y.; Shen, Z.; Guo, Y.; Jin, Y.; Shi, Q.; Chen, H.; Zhuang, Y.; Huang, W.; Che, J.; Dai, H.; Dong, X., 2024
Discovery of a Potent CDKs/FLT3 PROTAC with Enhanced Differentiation and Proliferation Inhibition for AML, Wu, M.; Wang, W.; Mao, X.; Wu, Y.; Jin, Y.; Liu, T.; Lu, Y.; Dai, H.; Zeng, S.; Huang, W.; Wang, Y.; Yao, X.; Che, J.; Ying, M.; Dong, X., 2024
Discovery of Potent CSK Inhibitors through Integrated Virtual Screening and Molecular Dynamic Simulation, Chen, R.; Wang, Y.; Shen, Z.; Ye, C.; Guo, Y.; Lu, Y.; Ding, J.; Dong, X.; Xu, D.; Zheng, X., 2024
Discovery and Characterization of Novel FGFR1 Inhibitors in Triple-Negative Breast Cancer via Hybrid Virtual Screening and Molecular Dynamics Simulations, Wang, Y.; Shen, Z.; Chen, R.; Chi, X.; Li, W.; Xu, D.; Lu, Y.; Ding, J.; Dong, X.; Zheng, X., 2024
Discovery of Potent Small Molecule Ubiquitin-Specific Protease 10 Inhibitors with Anti-Hepatocellular Carcinoma Activity through Regulating YAP Expression, Lu, Y.; Gao, J.; Wang, P.; Chen, H.; He, X.; Luo, M.; Guo, Y.; Li, L.; Zhuang, W.; Zhang, B.; Lin, N.; Li, J.; Zhou, Y.; Dong, X.; Che, J., 2024
Blocking Ubiquitin-Specific Protease 7 Induces Ferroptosis in Gastric Cancer via Targeting Stearoyl-CoA Desaturase, Guan, X.; Wang, Y.; Yu, W.; Wei, Y.; Lu, Y.; Dai, E.; Dong, X.; Zhao, B.; Hu, C.; Yuan, L.; Luan, X.; Miao, K.; Chen, B.; Cheng, X.-D.; Zhang, W.; Qin, J.-J., 2024
Discovery of Novel, Potent, Selective and Orally Bioavailable HPK1 Inhibitor for Enhancing the Efficacy of Anti-PD-L1 Antibody, Zeng, S.; Wu, M.; Jin, Y.; Ye, Y.; Xia, H.; Chen, X.; Che, J.; Wang, Z.; Wu, Y.; Dong, X.; Chen, Y.; Huang, W., 2024
Rational Identification of Novel Antibody-Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors, Guo, Y.; Shen, Z.; Zhao, W.; Lu, J.; Song, Y.; Shen, L.; Lu, Y.; Wu, M.; Shi, Q.; Zhuang, W.; Qiu, Y.; Sheng, J.; Zhou, Z.; Fang, L.; Che, J.; Dong, X., 2024
Discovery of N-(1-(6-Oxo-1,6-Dihydropyrimidine)-Pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium Tuberculosis, Yang, L.; Hu, X.; Lu, Y.; Xu, R.; Xu, Y.; Ma, W.; Alam, M. S.; Zhang, T.; Chai, X.; Lei, Y.; Ye, Q.; Dong, X.; Kang, Y.; Che, J.; Hou, T.; Li, D., 2024
Combining AI and Traditional Screening for Discovery of a Potent ROCK2 Inhibitor against Lymphoma, Lu, Y.; Shen, Z.; Shen, L.; Ying, J.; Gao, J.; Zhao, J.; Geng, S.; Chi, X.; Zhang, T.; Xu, L.; Zhang, Q.; Dong, X.; Xu, D., 2024
A Microenvironment-Responsive Small-Molecule Probe and Application in Quick Acute Myocardial Infarction Imaging, Lu, J.; Wu, Y.; Zhan, S.; Zhong, Y.; Guo, Y.; Gao, J.; Zhang, B.; Dong, X.; Che, J.; Xu, Y., 2024
Discovery of a Potent and Selective PARP1 Degrader Promoting Cell Cycle Arrest via Intercepting CDC25C-CDK1 Axis for Treating Triple-Negative Breast Cancer, Wu, Y.; Wu, M.; Zheng, X.; Yu, H.; Mao, X.; Jin, Y.; Wang, Y.; Pang, A.; Zhang, J.; Zeng, S.; Xu, T.; Chen, Y.; Zhang, B.; Lin, N.; Dai, H.; Wang, Y.; Yao, X.; Dong, X.; Huang, W.; Che, J., 2024
ADCdb: The Database of Antibody–Drug Conjugates, Shen, L.; Sun, X.; Chen, Z.; Guo, Y.; Shen, Z.; Song, Y.; Xin, W.; Ding, H.; Ma, X.; Xu, W.; Zhou, W.; Che, J.; Tan, L.; Chen, L.; Chen, S.; Dong, X.; Fang, L.; Zhu, F., 2024
Structure-Based Identification of New Orally Bioavailable BRD9-PROTACs for Treating Acute Myelocytic Leukemia, Zhang, J.; Duan, H.; Gui, R.; Wu, M.; Shen, L.; Jin, Y.; Pang, A.; Yu, X.; Zeng, S.; Zhang, B.; Lin, N.; Huang, W.; Wang, Y.; Yao, X.; Li, J.; Dong, X.; Zhou, Y.; Che, J., 2023
Identification of Potential JNK3 Inhibitors: A Combined Approach Using Molecular Docking and Deep Learning-Based Virtual Screening, Yao, C.; Shen, Z.; Shen, L.; Kadier, K.; Zhao, J.; Guo, Y.; Xu, L.; Cao, J.; Dong, X.; Yang, B., 2023
Peripheral immune cell profiling of double-hit lymphoma by mass cytometry, Lei, T.; Wu, Y.; Zhang, W.; Lu, J.; Han, S.; Zhuang, Y.; Dong, X.; Yang, H., 2023
TransFoxMol: predicting molecular property with focused attention, Gao, J.; Shen, Z.; Xie, Y.; Lu, Y.; Chen, S.; Bian, Q.; Guo, Y.; Shen, L.; Wu, J.; Zhou, B.; Hou, T.; He, Q.; Che, J.; Dong, X., 2023
A practical \"pre TACs-cytoblot” platform accelerates the streamlined development of PROTAC-based protein degraders, Rao, Z.; Li, K.; Hong, J.; Chen, D.; Ding, B.; Jiang, L.; Qi, X.; Hu, J.; Yang, B.; He, Q.; Dong, X.; Cao, J.; Zhu, CL., 2023
ClusterX: a novel representation learning-based deep clustering framework for accurate visual inspection in virtual screening, Chen, S.; Gao, J.; Chen, J.; Xie, Y.; Shen, Z.; Xu, L.; Che, J.; Wu, J.; Dong, X., 2023
Akt inhibitor Hu7691 induces differentiation of neuroblastoma cells, Bing, S.; Xiang, S.; Xia, Z.; Wang, Y.; Guan, Z.; Che, J.; Xu, A.; Dong, X.; Cao, J.; Yang, B.; Wang, J.; He, Q.; Ying, M., 2023
Discovery of Novel Oxazepine Derivatives as Akt/ROCK Inhibitiors for Growth Arrest and Differentiation Induction in Neuroblastoma Treatment, Che, J.; Bing, S.; Lu, J.; Jin, Z.; Gao, J.; Sheng, H.; Li, D.; Yang, B.; He, Q.; Ying, M.; Dong, X., 2023
An updated patent review of AKT inhibitors(2020-present), Li, L.; Guo, Y.; Lu, Y.; Xu，Y.; Lu, Y.; Zhu, X.; Dong, X.; Che, J., 2023
Targeted delivery of cathepsin-activatable near-infrared flurescenece probe for ultrahigh specific imaging of peritoneal metastasis, Lu, J.; Guo, Y.; Hao, H.; Ma, J.; Lu, Y.; Sun, Y.; Shi, Z.; Dong, X.; Zhang, B.; Fang, L.; Che,

Protein Degradation Druggability Optimization Ai Drug Design New Drug Discovery Targeted Therapy Pharmaceutical Chemistry Biological Chemistry Clinical Research

Xian Zeng - Fudan University

Yi-Fei Qi - Fudan University

Rong Sheng - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us